3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Breast Neoplasms
4
Urothelial Cancer
2
Urinary Bladder Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
1
Non Small Cell Lung Cancer NSCLC
1
Nasopharyngeal Carcinoma
1
Metastatic Urothelial Cancer
1
Metastatic Adenocarcinoma of the Pancreas
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Bile Duct Neoplasms
1
Interventions
pembrolizumab
3
tisotumab vedotin
2
Cisplatin
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
sacituzumab govitecan
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Vinorelbine
1
Trastuzumab
1
Topotecan
1
Sunitinib
1
Specimen Handling
1
Saline Solution
1
Pemetrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Uterine Cervical Neoplasms
×
Gemcitabine
×
Clear all
NCT04697628
2026-02-24
innovaTV 301
Seagen Inc.
Phase 3
Completed
502 enrolled
18 charts
1 FDA